Zhiwen Li - Sinphar Pharmaceutical Chairman of the Board
1734 Stock | TWD 30.85 0.25 0.82% |
Chairman
Li Zhiwen was Chairman of the Board in SINPHAR PHARMACEUTICAL CO. LTD. since June 7 1999. Li is also Chairman of the Board in three biotechnology companies including SUNETIC BIOTECH INC. and Director in an investment company. since 1999.
Tenure | 25 years |
Phone | 886 0 3958 1101 |
Web | https://www.sinphar.com.tw |
Sinphar Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0207 % which means that it generated a profit of $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0444 %, meaning that it generated $0.0444 on every $100 dollars invested by stockholders. Sinphar Pharmaceutical's management efficiency ratios could be used to measure how well Sinphar Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 4 records | CHAIRMAN Age | ||
ChiaChau Wu | Nan Ya Plastics | N/A | |
Yangwei Liu | Hon Hai Precision | N/A | |
Baolang Chen | Formosa Petrochemical Corp | N/A | |
ChiMau Sheih | Chunghwa Telecom Co | 69 |
Management Performance
Return On Equity | 0.0444 | |||
Return On Asset | 0.0207 |
Sinphar Pharmaceutical Management Team
Elected by the shareholders, the Sinphar Pharmaceutical's board of directors comprises two types of representatives: Sinphar Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinphar. The board's role is to monitor Sinphar Pharmaceutical's management team and ensure that shareholders' interests are well served. Sinphar Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinphar Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
ChihHsiao Chen, Head of Finance | ||
Zhiwen Li, Chairman of the Board | ||
Li Xie, Accounting Head |
Sinphar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sinphar Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0444 | |||
Return On Asset | 0.0207 | |||
Profit Margin | 0.07 % | |||
Operating Margin | 0.07 % | |||
Current Valuation | 6.26 B | |||
Shares Outstanding | 167.72 M | |||
Shares Owned By Insiders | 20.27 % | |||
Shares Owned By Institutions | 1.49 % | |||
Price To Earning | 536.84 X | |||
Price To Book | 1.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.